Tomiko Oskotsky

2 months ago | cell.com | Grace Ramey |Alice S. Tang |Thanaphong Phongpreecha |Monica Yang |Sarah R. Woldemariam |Tomiko Oskotsky | +6 more

Keywords autoimmunity Alzheimer’s bioinformatics case-control cohort electronic health records risk analysis sex differences statistical epidemiology Introduction Alzheimer’s disease (AD) is a debilitating neurodegenerative disease that is accompanied by enormous social and economic burdens, and its prevalence is increasing due to the growing aging population worldwide.1,2 AD is characterized biologically by amyloid plaques and tau deposition in the brain, while clinical syndromic diagnoses,...

Jul 4, 2024 | nature.com | Alice S. Tang |Beau Norgeot |Tomiko Oskotsky

AbstractWith the increasing availability of rich, longitudinal, real-world clinical data recorded in electronic health records (EHRs) for millions of patients, there is a growing interest in leveraging these records to improve the understanding of human health and disease and translate these insights into clinical applications. However, there is also a need to consider the limitations of these data due to various biases and to understand the impact of missing information.

Feb 20, 2024 | nature.com | Alice S. Tang |Jacquelyn Roger |Sarah R. Woldemariam |Riley Bove |Nima Aghaeepour |Tomiko Oskotsky | +1 more

AbstractIdentification of Alzheimer’s disease (AD) onset risk can facilitate interventions before irreversible disease progression. We demonstrate that electronic health records from the University of California, San Francisco, followed by knowledge networks (for example, SPOKE) allow for (1) prediction of AD onset and (2) prioritization of biological hypotheses, and (3) contextualization of sex dimorphism.

Apr 8, 2023 | nature.com | Sarah R. Woldemariam |Alice S. Tang |Tomiko Oskotsky

AbstractBackgroundAlzheimer’s dementia (AD) is a neurodegenerative disease that is disproportionately prevalent in racially marginalized individuals. However, due to research underrepresentation, the spectrum of AD-associated comorbidities that increase AD risk or suggest AD treatment disparities in these individuals is not completely understood.